ArticleTherapeutic advances in neurological disorders2013
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.
Article in Therapeutic advances in neurological disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis.European journal of clinical pharmacology · 2015Pooled it
- Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Guideline
- Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.British journal of clinical pharmacology · 2017Trial
- Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.PloS one · 2017Trial
- The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis.BMC neurology · 2014Trial
- Understanding the role of potential biomarkers in attenuating multiple sclerosis progression via multiomics and network-based approach.PloS one · 2024Article
- Interferon β, an enhancer of the innate immune response against SARS-CoV-2 infection.Microbial pathogenesis · 2021Review
- Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis.Journal of clinical neurology (Seoul, Korea) · 2018Article
- Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.The AAPS journal · 2018Review
- Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.Scientific reports · 2017Article
- Early implementation of QbD in biopharmaceutical development: a practical example.BioMed research international · 2015Review
- Interleukin-17 (IL-17)-induced microRNA 873 (miR-873) contributes to the pathogenesis of experimental autoimmune encephalomyelitis by targeting A20 ubiquitin-editing enzyme.The Journal of biological chemistry · 2014Article
- Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.Advances in therapy · 2014Review
- Identifying responders and nonresponders to interferon therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2014Article
- Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Neuropsychiatric disease and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopharmaceuticals are drugs which are based on naturally occurring proteins (antibodies, receptors, cytokines, enzymes, toxins), nucleic acids (DNA, RNA) or attenuated microorganisms. Immunogenicity of these agents has been commonly described and refers to a specific antidrug antibody response. Such immunogenicity represents a major factor impairing the efficacy of biopharmaceuticals due to biopharmaceutical neutralization. Indeed, clinical experience has shown that induction of antidrug antibodies is associated with a loss of response to biopharmaceuticals and also with hypersensitivity reactions. The first disease-specific agent licensed to treat multiple sclerosis (MS) was interferon-β (IFNβ). In its various preparations, it remains the most commonly used first-line agent. The occurrence of antidrug antibodies has been extensively researched in MS, particularly in relation to IFNβ. However, much controversy remains regarding the significance of these antibodies and incorporation of testing into clinical practice. Between 2% and 45% of people treated with IFNβ will develop neutralizing antibodies, and this is dependent on the specific drug and dosing regimen. The aim of this review is to discuss the use of IFNβ in MS, the biological and clinical relevance of anti-IFNβ antibodies (binding and neutralizing antibodies), the incorporation of testing in clinical practice and ongoing research in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.